Combination Immunotherapies

• 1547 IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma Eleni Panagioti, Hunter J. Kelley, Alexander L. Ling, William Goins, Daniel Roberts, Sotiris Sotiriou, Bryan J. Iorgulescu, Karen Dixon, Michael B. Yaffe, Maria G. Castro, Sean E. Lawler, Gordon J. Freeman, Vijay K. Kuchroo, E Antonio Chiocca, Charles H. Cook
• 1548 T-cell acute lymphoblastic leukemia (T-ALL) drives robust T cell responses that can be harnessed with aCD40 and aPD1 combination therapy Faizah Alabi, Alex Somma, Todd Triplett
• 1549 · PDF Non-clinical characteristics of BH3120, a clinical stage bispecific antibody targeting PD-L1 and 4-1BB, in combination with CD3 T cell engagers Jing Wang, Jun Wang, Yang Liu, Aibo Sun, Aihong Zhang, Haixia Zhao, Renai Guo, Jie Feng, Jiangcheng Xu, Jiawang Liu, Kyoungwoo Lee
• 1551 · PDF Intratumoral biodegradable nanofluidic platform for localized multimodal immunotherapy enhances tumor eradication and immune memory Jingyi Wang, Francesco Manfredi, Eleonora Molinari, Madison A. Deeson, Danilo Settis, Casey Lewis, Junjun Zheng, Junhua Mai, Shu-Hsia Chen, Corrine Ying Xuan Chua, Alessandro Grattoni
• 1552 · PDF Epigenetic induced increased chromatin accessibility of immune activation loci is associated with response to anti-PD-1 therapy Otega Oviri, Tyler Gross, Md Imran Khan, Sean Henry Colligan, Jonathan E. Bard, Roberto Pili
• 1553 · PDF Combining PD-1 blockade with DLL3-targeted T cell engager potentiates antitumor efficacy in small cell lung cancer Tongxin Huo, Ting Ni, Jingjing Wang, Panpan Wang, Yuhe Han, Yawen Zhang, Jian Xiang, Zhixiang Zhang
• 1554 · PDF Combining an optimized irinotecan formulation with self-amplyfing RNA to treat an immunosuppressive lung metastasis melanoma model XuXin Sun, Nasim Sarrami, Irafasha C. Casmil, Sijie Zhang, Marcel B. Bally, Anna K. Blakney
• 1555 · PDF Differential tumor and immune responses to anti PD-1 and DGK inhibition in patient-derived tumor spheroids reveal additive killing effect Bihui Melidosian, Julia Vail, Xiaodi Ren, Danielle Hagee, Michael A. Perricone, Cynthia Timmers
• 1556 · PDF NK cells activated by monoclonal antibody-coated target cells enhance bispecific antibody-induced T cell proliferation, activation and cytotoxicity Reza Amani, Jyoti Arora, George J. Weiner
• 1557 · PDF PHST001 combination with standard-of-care chemotherapy enhances macrophage-mediated elimination of tumor cells Giovanni C. Forcina, Kelsey E. Hart, Joseane Sampaio, Joshua D. Rudolph, Suzana A. Kahn, Raphaël F. Rousseau, Amira A. Barkal, Ravindra Majeti, Irving L. Weissman, Roy L. Maute, Jennifer Yinuo Cao
• 1558 · PDF Preclinical activity of ziftomenib and CAR T cell immunotherapy in KMT2A -rearranged (R) acute leukemias Sarah E. Haines, Shubhmita Bhatnagar, Michael C. Yarnell, Samantha M. McClellan, Catherine D. Falkenstein, Linda Kessler, Francis J. Burrows, Lisa M. Niswander, Terry J. Fry, Sarah K. Tasian
• 1559 · PDF First-in-class Zalpha-domain-targeted ADAR1 p150 inhibitor demonstrates potent antitumor efficacy in high IFN syngeneic melanoma Aditya Kulkarni, Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Barnali Deb
• 1560 · PDF Targeting the non-canonical immune checkpoint MUC1-C enhances anti-PD-1 therapy in solid tumors Dae Young Kim, Hee Young Kang, Young Ha Yoon, Sung Min Kim, Hoil Choi
• 1561 · PDF Overcoming immunosuppression in pancreatic cancer: Efficacy of polyamine blockade and anti-PD-1 combinational therapy Joseph A. Goode, Diana Estefania Gaete-Alvarez, Savannah Harris, Otto Phanstiel, Deborah A. Altomare
• 1562 · PDF Rewiring the immune-excluded tumor microenvironment: Vactosertib/anti-PD-1/VEGF inhibitor triplet therapy reinstates antitumor immunity in CRC Seong-Jin Kim, Dong Woo Kang, Hye Jin Kim, Seonho Yoo, Jin Beom Bae, June Myoung Kim, Min Kyu Kim, Jinhwan Kim, Jin Su Kim, Ye Seon Kim, Jeong Su Lee, Kwiyeom Yoon
• 1563 · PDF Intratumoral IL-12 in combination with HDAC inhibition overcomes checkpoint-refractory tumors Asma S. Khelifa, Ainara Meler, Christine M. Minnar, Katherine E. Lothstein, Masaya Miyamoto, Nicholas Roller, Lisa K. Poppe, David Peeney, Sailaja Battula, Howard L. Kaufman, Jeffrey Schlom, Sofia R. Gameiro
• 1564 · PDF Bortezomib enhances anti-tumor efficacy of PD-1 blockade in lung squamous cell carcinoma via innate immune activation Xin Jin, Jianguo Zhong, SIbo Peng, Song Xu
• 1565 Analyzing Tumor Treating Fields (TTFields) therapy concomitantly with checkpoint inhibitors in a GBM mouse model Si Yeon Lee, Kwang Bog Cho, Caren Wu, Justin Liu, Joe Ha, Adam Sjoholm, Michael Lim, Gordon Li, Ryan Nitta
• 1566 · PDF Genetic and pharmacologic targeting of host ATF4 sensitizes pancreatic ductal adenocarcinoma to CAR T and immune checkpoint blockade Nektarios Kostopoulos, Rohan Ganesh, Tej Patel, Frank Chinga, Dan Boehmler, Arjun Sengupta, Aalim Weljie, Costa Koumeis
• 1567 · PDF Reprogramming of exhausted T cells in pancreatic cancer with SBRT/IL-12 therapy Sarah Eckl, Gary Hannon, Angela Hughson, Scott A. Gerber
• 1568 · PDF Synergistic antitumor effects of immune checkpoint inhibitors and targeted therapy in an orthotopic RCC mouse model Balaji Ramachandran, Satheeshkumar Rajendiran, Abhilash Reddy, Girish Joshi, Krishnappa Haladasappa
• 1569 · PDF Treatment of PAX3-FOXO1 alveolar rhabdomyosarcoma with ICP34.5-armed G47∆ oncolytic herpes simplex virus confers survival benefit when co-administered with anti-Pd1 antibody Cole W. D. Peters, Miriam Valenzuela-Cardenas, Moe Kawakami, Andrew Dinh, Jaden Nguyen, Allison Flores, Theodore S. Nowicki
• 1570 · PDF Preclinical assessment of EGFR and checkpoint inhibitor combination therapy in spontaneous colon cancer model Balaji Ramachandran, Satheeshkumar Rajendiran, Girish Joshi, Krishnappa Haladasappa
• 1571 · PDF CAF-mediated cancer immunotherapy resistance can be overcome via selective inhibition of NOX1, 2 and 4 Jihyun Um, Heesu Kim, Hye Ji Jang, Eun Sil Lee, Yeonhee Ahn, Sung Hwan Moon, Soo Jin Lee
• 1572 · PDF Cocktail immunotherapy: Plant virus immunomodulator, HER2 antibody, and co-delivered IL-12 cytokine for the treatment of HER2+ cancer Ayumi E. Pottenger, Miguel A. Moreno Gonzalez, Manuel L. Penichet, Nicole F. Steinmetz
• 1575 · PDF Immune implications of dual PIKfyve and KRAS inhibition in pancreatic ductal adenocarcinoma Jasmine P. Wisniewski, Caleb Cheng, Rüya Pakkan, Sydney Peters, Gabriel Cruz, Yuanyuan Qiao, Costas A. Lyssiotis, Arul M. Chinnaiyan
• 1576 · PDF Combination treatment of mertki and immunomodulatory chemotherapy results in cxcl9 positive macrophage reprogramming and anti tumor adaptive memory in triple negative breast cancer Alex J. Smith, Zachary Schrank, Nan Guan, Diego Pedroza, Sebastian Calderon, Xueying Yuan, Na Zhao, Zoe Gabriel, Yang Gao, Charlotte Rivas, Fengshuo Liu, Chuck Perou, Shelton Earp, Jeffrey M. Rosen

在完整检索应用中浏览本分会场 →